COVID-19 mortality in patients with immunodeficiency and its predictors: a systematic review

SeyedAhmad SeyedAlinaghi1, Amirali Karimi2, Alireza Barzegary3, Hengameh Mojdeganlou4, Farzin Vahedi2, Seyed Peyman Mirghaderi2, Parnian Shobeiri2, Maryam Ramezani5, Parisa Yousefi Konjdar6, Pegah Mirzapour1, Marcarious M. Tantuoyir2,7, Esmaeil Mehraeen8*, Omid Dadras9 and Fabricio Voltarelli10

Abstract
Introduction: Patients with immunodeficiency are usually more prone to worse outcomes of infectious diseases. However, there are some disagreements in the context of COVID-19, for example, in patients with human immunodeficiency virus (HIV). Herein, we aimed to systematically review the risk and predictors of COVID-19 mortality in people with primary or secondary immunodeficiency.

Methods: PubMed, Scopus, Web of Science, and Science Direct were searched. We followed a two-step screening process to identify eligible results. We first reviewed the title and abstract of the records and the unqualified studies were removed. Then, their full texts were evaluated based on their coherence with the purpose and inclusion/exclusion criteria, and those eligible for qualitative synthesis were included.

Results: Twenty-two articles were included, which investigated a total of 109,326 with primary or secondary immunodeficiencies. Three studies investigated the pediatric and infant population, while other studies were conducted on the adult population. Overall, studies on both primary and secondary immunodeficiency conflicted as some reported higher and some mentioned lower mortality rates in patients with immunodeficiency.

Conclusions: Overall, there were two points of view in both types of immunodeficiencies. The first is the classical viewpoint that all immunodeficient patients are at a higher risk of infection leading to a higher mortality rate. The second types of studies found that immunodeficiency might play a less important or even an inverse role in mortality rates by lowering the severity of the inflammatory response. However, it is important to take note to comorbidities, such as DM, HTN, CAD, ESRD, history of lower respiratory infection, etc., and demographic factors, such as obesity and age > 70 years, as they appear to influence the mortality rate, especially in patients with secondary immunodeficiency.

Keywords: COVID-19, Immunocompromised, Immunodeficiency, Immunosuppression, Impaired immune response, SARS-CoV-2, Comorbidities

Introduction
Since December 2019, a fatal respiratory disease named coronavirus 2019 (COVID-19) has spread worldwide [1, 2]. It has quickly progressed from a few pneumonia-like cases to a pandemic that is still spreading. Humoral immune response, in particular the creation of neutralizing antibodies, serves as a protective mechanism by...
delaying the onset of infection [3–5]. Severe acute respiratory syndrome-Coronavirus 2 (SARS-CoV-2) infection can potentially influence a wide range of human organs, and infected people may show a sort of symptoms that may vary from person to person [6–9]. Apart from the tremendous potential of the novel coronavirus in impairing the respiratory system, its quick propagation and propensity to engage numerous hosts in severe cases of infections or immunopathological consequences make it a challenging opponent for the immune system [10]. The interplay between SARS-CoV-2 and the host immune system result in unleashing massive numbers of cytokines secretion [11, 12]. The cytokine storm introduces a dangerous situation that determines the clinical course (healing or mortality) and may lead to multi-organ failure [13, 14].

Some studies claimed that immunodeficient and immunocompromised patients have poorer prognoses and outcomes and higher mortality rates than healthy people, but the outcome and prognosis mainly depend on the type and level of immunodeficiency. Moreover, the wide range of microorganisms that cause infection has different prognoses in immunodeficient people [15, 16].

Regarding COVID-19, however, conflicting results exist between immunodeficiency and the risk of severe outcomes [17–19].

Considering the current COVID-19 pandemic, it is highly important to improve the surveillance and management of immunodeficient people to reduce mortality and morbidities among them [19]. Therefore, actions must be developed based on scientific facts to decreased devastating outcomes, and this requires a comprehensive review of current literature to provide precise prediction models and improve the outcomes of COVID-19 infection in immunocompromised patients. As clinicians, we should assess the patterns of mortality and comorbidities in immunodeficient patients to design a well-organized system to provide care when needed [20]. This assessment of patterns of the disease might be the key to reduce its mortality and comorbidities. For instance, the United Kingdom Primary Immunodeficiency Network has developed a system to systematically follow PID (primary immunodeficiency) and SID (secondary immunodeficiency) patients and record their COVID-19 infection status as well as outcomes [21]. Given this background, we systematically reviewed studies on immunodeficient people infected with COVID-19 regarding their risk factors and subsequent predictors of mortality rates.

**Materials and methods**

This study is a systematic review of current literature conducted in March 2021. The authors studied COVID-19 mortality in patients with immunodeficiency and its predictors. Our study was conducted according to the Preferred Systematic Review and Meta-Analysis Report (PRISMA) to ensure the reliability and validity of the results.

**Data sources**

Using systematic searches and keywords in online databases, including PubMed, Scopus, Web of Science, and Science Direct, we extracted all relevant articles published in English up to March 2021. We have included several combinations of keywords in the following commands to perform a search strategy: (1) “COVID-19” or “SARS-CoV-2” [title/abstract]; (2) “Immunocompromised” [Title/Abstract] (3) “Immunodeficiency” [Title/Abstract] (4) “Immunosuppression” [Title/Abstract] (5) “Impaired immune response” [Title/Abstract].

**Inclusion/exclusion criteria**

The original, English, and peer-reviewed studies that reported the outcomes of COVID-19 in patients with immunodeficiency were included.

Exclusion criteria were as follows: (1) abstracts or the articles whose full-text was not available, (2) text written in any other language except English, (3) and non-original articles (editorials, reviews, etc.), (4) studies that were not peer-reviewed, or (5) animal or laboratory (non-human) studies.

**Study selection**

Two independent researchers selected relevant studies screening the titles and abstracts of the retrieved records. After that, the full-text of the retrieved articles was reviewed, and the most relevant articles were selected according to the eligibility criteria. Then, we extracted the relevant data and organized them into tables.

**Data extraction**

After summarizing, we transferred the study information, the first author (reference), type of study, country, study population, age (average), gender, primary immunodeficiency, secondary immunodeficiency, laboratory factors, clinical factors, underlying disease, and mortality rate (N(%)) to a data sheet. Two independent researchers collected this information and subsequently organized it into tables. Finally, all articles selected by other authors were reviewed to ensure that there was no duplication or overlap in the content.

**Risk of bias/quality assessment**

We assessed the risk of bias/quality of the studies using the Newcastle–Ottawa scale (NOS) checklist. This scale allocates a 0–9 score to each study based on selection,
comparability, and exposure/outcome [22]. Studies that scored 4 or below were considered of poor quality.

**Results**

A total of 850 articles were retrieved from our comprehensive search strategy. After removing duplicates and screening the title/abstract followed by full-text evaluation for eligibility, 22 articles were included in the final narrative data synthesis. The exact details of the selection process are illustrated in Fig. 1.

The study design distribution of the selected studies is represented in Table 1, which were mainly retrospective studies. Most of the studies were conducted in the USA ($n = 10$), UK ($n = 4$), and Spain ($n = 2$). The selected studies investigated a total of 109,326 patients cumulatively, that suffered from primary immunodeficiency (common variable immune deficiency [CVID], humoral...
immunodeficiencies, etc.) or secondary immunodeficiency (HIV, malignancy, etc.). Three studies investigated the pediatric and infant populations [21, 23, 24], while other studies were conducted on the adult population. Table 2 displays the information extracted from the included articles.

**Primary immunodeficiency disorders (PID)**

Delavari et al.'s study [24] showed considerably higher mortality than the general population among PID patients with combined immunodeficiency and immune dysregulation, even with the same rate of COVID-19 infection incidence. In line with Delavari, A.M. Shields's study claimed patients with PID and symptomatic SID are at higher risk of morbidity and mortality from COVID-19 [21]. However, the case studies by Fill et al. and van Oers et al. [23, 25] represented cases with PID, which both recovered successfully without a fulminant course of disease. The authors hypothesized that immunosuppression might help prevent severity and mortality due to COVID-19. In addition, a study by B. Cohen et al. [19] suggested that patients with immunodeficiency are not at a greater risk for COVID-19 mortality and disease severity. Besides, Meyts I. et al.'s study [26] on patients with inborn errors of immunity (IEI) confirmed comparable manifestations and risk factors for mortality and morbidity among these patients and the general population.

**Secondary immunodeficiency (SID)**

The primary outcome that was sought in the immunodeficient patients in the present review was the mortality rate. The mortality rate ranges from 0.09% [17] to 28.6% [27] in HIV patients, as a major part of secondary immunodeficient. Five studies [17, 28–31] found HIV infection as a deteriorating factor in the severity and outcome of the COVID-19 patients, with the catastrophic outcome especially in the black race [17, 28]. However, eight studies [18, 27, 32–37] suggested that HIV-infected patients have no worse or higher incidence than the normal population.

**Risk of bias/quality assessment**

All the studies had acceptable quality based on the NOS; therefore, no studies were excluded from this systematic review due to poor quality. The most encountered problem that could contribute to a possible introduced risk of bias was the lack of matching for the two groups of cases and controls in some studies (Table 3).

**Discussion**

Due to emergence of COVID-19 pandemic, understanding the difference between the reaction of the immune system in patients with and without underlying conditions has been a matter of debate [41, 42]. This systematic review analyzed a total of 22 different studies that met the inclusion criteria and sought to establish the predictors and mortality rate in COVID-19 patients who have weak immune systems otherwise known as immunocompromised or immunodeficient patients. The different immune system conditions as seen in suppressive situations have been attributed to the severity, mortality, and high infection rate of the diseases [15]. This category of patients has been a point of attention from the start of the COVID-19 pandemic, since they are more prone to infectious diseases and classified as one of the high-risk groups of patients. Breakdown of the study type included in our analysis can be seen in Table 2 and the flow of inclusion criteria is represented in Fig. 1. Immunodeficient patients are widely categorized into primary and secondary immunodeficiencies with markedly decrease or absent immune cells or system function, and thus, for a better assortment of this study, we separated the cases into these two categories of patients.

The first one is the cases reported with the PID, such as CVID, humoral immunodeficiency, etc. PID refers to a diverse set of illnesses caused by flaws in the immune system's development and/or function. PIDs have a wide range of signs and symptoms, but the majority of them involve an elevated susceptibility to infection, with several of them resulting in substantial disease-related adverse outcomes (morbidity and mortality). This point of view might seem logical and reasonable in the first place and lead us to the idea that having PID might increase the mortality of the COVID-19 patients as stipulated by the findings of Delavari et al. study in which they found that even though COVID-19 is normally a minor disease in children and adolescents (due to low ACE2 receptor expression and effective adaptive immunity), a small percentage of individuals, particularly adaptive immunity, may suffer severe disease necessitating transfer to an intensive care unit (ICU) and even death [24]. Meyts I et al. also found that younger patients with inborn errors of immunity (IEI) were more severely affected and more
| ID | First author (reference) | Study population | COVID-19 mortality details | Mortality Rate [N (%)] |
|----|--------------------------|------------------|---------------------------|----------------------|
| 1  | Bhaskaran K [17]         | N = 17,282,905 [HIV-infected N = 27,480 (0.16%)] | Median = 48 (40–45) Male (n = 17780 (64.7%)) Primary immuno deficiency – Secondary immuno deficiency – Laboratory factors – Clinical factors Current or former Smoker (5.1%) Underlying disease Hypertension (19.3%) Cardiovascular disease (4.0%) Stroke or dementia (2.0%) Other neurological disease (0.9%) Organ transplant (0.3%) Asplenia (0.3%) RA, lupus, or psoriasis (4.5%) Other immunosuppressive (0.2%) Diabetes mellitus (9.8%) non-hematological cancer (4.7%) Hematological malignancy (2%) chronic Renal failure (0.5%) Other HIV-infected patients have higher risk of COVID-19 death: hazard ratio (HR) = 2.90 the association was larger in Black individuals (HR = 4.31) |
| 2  | Cabello A [18]           | N = 18853 (HIV-infected = 63) | Median = 46 (37–56) Male n = 56 (88.9%) – HIV Lymphopenia (26.5%) Ferritin > 1000 mcg/L (25%) D-dimer > 2500 ng/mL (4.8%) CD4+ < 200 cells/µL (83.3%) Nadir CD4 < 200 cells/µL (25.4%) HIV infection time (years) = 10.8 ART N = 61 (96.8%) virological suppression time (years) = 7.2 Current or former Smoker (48.2%) COMO-19 diagnosis: laboratory confirmed (49.2%), clinically suspected (50.8%) duration of symptoms (days) before treatment = 6 Pneumonia (47.5%) WHO COVID-19 severity score (28.6%) Hospital admission (52.5%) Previous comorbidity (84.1%) Hypertension (19%) Diabetes mellitus (9.5%) Overweight 13.1% cardiovascular disease (12.7%) Chronic respiratory disease (4.8%) chronic Renal failure (3.2%) | 3.17% |
| 3  | Childs K [28]            | N = 18 | Median = 52 (49–58) Male n = 12 (67%) – HIV Preadmission CD4 count, cells/µL = 395 Nadir CD4 count, cells/µL = 97 HIV RNA < 50 copies/ml = 1794 Hypoalbuminemia = 1100 Lymphocytes = 1100 CRP = 143 (72–253) HIV infection time (years) = 14.6 Smoker = 0 (0%) duration of COVID-19 symptoms at admission (days) = 8 Cough (72%) Dyspnea (67%) Fever (61%) Pneumonia (72%) AKI (28%) requiring mechanical ventilation = 5 (28%) Obesity (BMI > 30 kg/m²) (56%) Hypertension (3%) Diabetes mellitus (22%) Chronic kidney disease (28%) | 27.8% |
Table 2 (continued)

| ID | First author (reference) | Study population | COVID-19 mortality details | Mortality Rate [N (%)] |
|----|--------------------------|------------------|---------------------------|-----------------------|
|    |                          |                  |                           |                       |
| 4  | Cohen B[19]               | N = 135 N = 10 (COVID-19 positive) | 37 Male = 6 (60%)     | 0%                    |
|    |                          |                  | CVID                      |                       |
|    |                          |                  | –                        |                       |
|    |                          |                  | Lymphopenia 3 (30%)      |                       |
|    |                          |                  | Pneumonia (0%)            |                       |
|    |                          |                  | requiring mechanical ventilation = 0 (0%) |                       |
|    |                          |                  | mild to moderate symptoms = 9 (90%) |                       |
|    |                          |                  | on biological therapies = 2 (20%) |                       |
|    |                          |                  |                      |                       |
|    |                          |                  | Underlying disease        |                       |
|    |                          |                  | CVID patients are not at a higher risk for mortality and worse outcome |                       |
|    |                          |                  | Standardized risk per 10,000 between the 77,590 HIV-positive persons = 30.0 for COVID-19 diagnosis = 3.7 for death greater risk in men and age > 70 years lower risk (2.5) for TDF/FTC regime incidence of COVID-19 in HIV-infected population is comparable to the normal population TDF/FTC treatment may have beneficial impact for patients with COVID-19 and HIV co-infection | 8%                    |
| 5  | Del Amo J [32]            | N = 77,590 (HIV-infected persons receiving ART) N = 236 (COVID-19 positive) | 48.9 Male = 58, 120 (75) | 8%                    |
|    |                          |                  | –                        |                       |
|    |                          |                  | HIV                      |                       |
|    |                          |                  | –                        |                       |
|    |                          |                  | Hospital admission 151 (64%) |                       |
|    |                          |                  | median duration of hospitalization for discharged patients (day) = 7 (4–10) |                       |
|    |                          |                  | ICU admission 15 (6%), death 20 (8%) |                       |
| ID | First author (reference) | Study population | COVID-19 mortality details | Mortality Rate [N (%)] |
|----|--------------------------|------------------|---------------------------|------------------------|
| 6  | Delavari S [24]          | N = 2754 with primary immuno-deficiencies (PIDs). N = 19 (0.68% PIDs with COVID-19 positive) | Male = 1756 (63.8%) | 42.1% |
|    |                          |                  | Primary immuno-deficiencies (PIDs): Combined immuno-deficiencies (n = 1392) humoral immuno-deficiencies (n = 1391) phagocytic defects (n = 762) immune dysregulation (n = 117) autoimmune inflammatory disorders (n = 734) complement deficiency and innate immuno-deficiencies (n = 304) | 1.23 folds higher risk of COVID-19 infections (0.68%) Tenfolds higher mortality rate (0.003%) most mortality rate of COVID-19 infection: SCID patient (0.03%) and FHL (0.027%) |
| 7  | Fill L [25]              | A CVID positive patient (confirmed by PCR) | Female | 42.1% |
|    |                          |                  | CVID | duration of COVID-19 symptoms at admission (day) = 7 chest CT-scan = multifocal ground-glass opacities Admission to ICU (day 4) Mechanical ventilation (day 7) ARDS | CVID breast cancer hypothyroidism Sjögren's syndrome | recovered |
| ID | First author (reference) | Study population | COVID-19 mortality details | Mortality Rate [N (%)] |
|---|--------------------------|-------------------|---------------------------|-----------------------|
| 8 | Gamboa E (38) | A co-infection of HIV and COVID-19 case (confirmed by PCR) | 59 Male – HIV | Recovered (after 2-week hospitalization) |
| 9 | Geretti AM (39) | N=47,592 COVID-19 patients (confirmed by PCR) N=122 (0.26% with HIV-infection) | 56 (49–62) Male = 80 (66.1%) – HIV | HIV infection does not increase admission to critical care |
### Table 2 (continued)

| ID | First author (reference) | Study population | COVID-19 mortality details | Other |
|----|--------------------------|------------------|---------------------------|-------|
| 10 | Gervasoni C [33] | N = 47 Co-infection HIV and COVID-19 | 51 (± 11) Male = 36 (77%), – HIV | HIV-infected patients with COVID-19 are at the same risk of severe disease or death as the normal population |
| | | | CD4 + cells/µL = 636 (± 290) HIV viral load < 20 copies/ml = 44 (94%) | |
| | | | Disease duration (day) = 14 | |
| | | | COVID-19 diagnosis laboratory confirmed (60%), clinically suspected (50.8%) | |
| | | | Hospital admission: 13 (28%) Pneumonia 12 (25%) | |
| | | | Underlying disease Other |
| | | | Previous comorbidity (64%) Dyslipidemia (51.9%) Hypertension (29.8%) Hepatitis C or B co-infection (10.64%) renal disease (8.5%) Diabetes mellitus (6.4%) epilepsy (2%) cardiovascular disease (4.3%) malignancy (6.4%) gastritis (4.3%) organ transplant (2.1%) Chronic respiratory disease (4.3%) |
| 11 | Hadi YB [29] | N = 50,167 COVID-19 patients (HIV-infected = 404) | 48.2 (SD 14.2) Male = 285 (71%) – HIV | in unmatched analysis: HIV-infected patients showed higher mortality (risk ratio 1.55) and higher inpatient service need (RR = 1.83) After propensity score matching: no difference in mortality rate, but still higher inpatient service needs in HIV-infected patients |
| | | | CRP mg/L = 71.15 LDH U/L = 372.45 (SD = 291.05) ESR = 52.89 ALT U/L = 37.2 AST U/L = 48.43 Bilirubin mg/L = 0.84 Ferritin ng/mL = 23,646.94 | |
| | | | ICU admission = 2.7 (6.7%) Current or former Smoker (13.86%) | |
| | | | Hypertension (46.29%) Chronic respiratory disease (2.5%) Diabetes mellitus (2.03%) Chronic kidney disease (16.58%) | |
| | | | in unmatched analysis: HIV-infected patients showed higher mortality (risk ratio 1.55) and higher inpatient service need (RR = 1.83) After propensity score matching: no difference in mortality rate, but still higher inpatient service needs in HIV-infected patients |
| 12 | Härter G [34] | N = 33 Co-infection HIV and COVID-19 | 48 (range 26–82 years) Male = 30 (90.9%) – HIV | No increased morbidity and mortality among symptomatic COVID-19 co-infection with HIV on ART |
| | | | Median CD4 + T-cell = 670 cells/µL HIV RNA < 50 copies/ml = 30 (93.75%) | |
| | | | Mild symptoms (76%) severe (6%) critical (18%) requiring mechanical ventilation = 2 (6.1%) ICU admission = 6 (18.2%) Hospital admission (4.2%) | |
| | | | Previous comorbidity (80.0%) Hypertension (30.3%) Chronic respiratory disease (18.2%) diabetes mellitus (12.1%) cardiovascular disease (9.1%) chronic renal failure (6.1%) Hepatitis B co-infection history (15.2%) | |
| ID  | First author (reference) | Study population | COVID-19 mortality details | Mortality Rate | Mortality Details |
|-----|-------------------------|------------------|---------------------------|----------------|------------------|
| ID  | First author (reference) | Study population | COVID-19 mortality details | Mortality Rate | Mortality Details |
| 13  | Ho H-e [30]              | N=93 Co-infection HIV and COVID-19 | 58 (52–65) Male =67 (72%) | 19 out of 93 (20.4%) | Died patients have significant lower nadir absolute lymphocyte count and higher levels of inflammatory markers. |
|     |                         |                  | during COVID-19 illness: significant lymphopenia and decreased CD4 + T-cell counts and percentages Nadir CD4+, cells/µL = 220 CD4% = 29 HIV RNA < 50 copies/ml (89.1%) Nadir WBC, cells/µL = 5100 Nadir ALC, cells/µL = 900 Nadir ANC, cells/µL = 3500 ALT U/L = 45 AST U/L = 61 Total bilirubin, mg/dl = 0.7 ALP, U/L = 96 Increased levels of inflammatory markers: CRP, mg/L = 13.0 Fibrinogen, mg/dl = 606 D-dimer, µg/mL = 2.6 IL-6, pg/mL = 57.6 IL-8, pg/mL = 42.2 TNF-α, pg/mL = 21.8 IL-1β, pg/mL = 0.3 | 19 out of 93 (20.4%) | Died patients have significant lower nadir absolute lymphocyte count and higher levels of inflammatory markers. |
|     |                         |                  | hospital admission (77.4%) ICU admission (20.4%) mechanical ventilation = 15 (16.1%) Current or former smoker (5.4%) | 19 out of 93 (20.4%) | Died patients have significant lower nadir absolute lymphocyte count and higher levels of inflammatory markers. |
|     |                         |                  | Laboratory factors: | 19 out of 72 hospitalized individuals (26.4%) | Died patients have significant lower nadir absolute lymphocyte count and higher levels of inflammatory markers. |
|     |                         |                  | Clinical factors: | 19 out of 72 hospitalized individuals (26.4%) | Died patients have significant lower nadir absolute lymphocyte count and higher levels of inflammatory markers. |
|     |                         |                  | Underlying disease: | 19 out of 72 hospitalized individuals (26.4%) | Died patients have significant lower nadir absolute lymphocyte count and higher levels of inflammatory markers. |
|     |                         |                  | Other: | 19 out of 72 hospitalized individuals (26.4%) | Died patients have significant lower nadir absolute lymphocyte count and higher levels of inflammatory markers. |
|     |                         |                  | | 19 out of 72 hospitalized individuals (26.4%) | Died patients have significant lower nadir absolute lymphocyte count and higher levels of inflammatory markers. |
| ID | First author (reference) | Study population | Age (average) | Gender | Primary immuno deficiency | Secondary immuno deficiency | Laboratory factors | Clinical factors | Underlying disease | Other |
|----|--------------------------|------------------|---------------|--------|---------------------------|---------------------------|-------------------|----------------|------------------|-------|
| 14 | Karmen-Tuohy S [27]      | N = 63 patients hospitalized with COVID-19 (HIV-positive N = 21 and matched non-HIV: N = 42) | –             | –      | HIV                       | –                         | On admission: WBC = 7200, Hemoglobin = 12.70, Absolute neutrophil count = 5800, Absolute lymphocyte count = 1090 (higher in HIV positives) Ferritin = 679, D-dimer = 333, Troponin = 0.02, Creatine phosphokinase = 239, Procalcitonin = 0.2, Creatinine = 1.14, CRP = 15.45 (higher in HIV positives) LDH = 4494, absolute CD4 count = 298, CD4 count < 200/mL (31.6%), CD4% = 24, viral load < 50 copies/mL (88.2%) | Length of hospital stay d = 6, ICU admission = 6 (28.6%), mechanical ventilation = 5 (23.8%), Abnormal initial chest X-ray 19 (90.5%)—(higher in HIV positive patients)—no difference for abnormal chest X-ray ever-present during this hospitalization Complications: Myocardial infarction = 1 (4.8%), Pulmonary embolism = 1 (4.8%), Deep vein thrombosis = 1 (4.8%), bacterial pneumonia = 3 (14.3%) | – | No difference in length of the hospital stays, rates of ICU admission, mechanical ventilation, and mortality | 28.6% |
| 15 | N.S.C. van Oers [23]     | An infant with X-SCID | Infant | Male | X-SCID | – | – | hepatitis | X-SCID | He received a haploidentical CD34 selected stem cell transplant | 0% |
| 16 | Douglas Tremblay [40]    | 24 cancer patients treated with convalescent plasma for severe COVID-19 | 58.3% male | – | Cancer Hematologic malignancy (50%), Solid malignancy (42%) | Neutropenic (0%), Lymphocytopenic (58.3%) | 95.9% required supplemental oxygen, 16.7% require NPPV, 12.5% were intubated | HTN 6.2%, DM 33%, CKD 29%, CAD 21%, COPD 20%, CHF 20%, Obesity 20% | – | 41.7% |
| ID | First author (reference) | Study population | COVID-19 mortality details | Mortality Rate [%] |
|----|--------------------------|------------------|---------------------------|-------------------|
|    |                          |                  |                           |                   |
| 17 | K. Sigel [35]            | 88 PLWH hos-      | 61                         | 21%               |
|    |                          | pitalized with   |                           |                   |
|    |                          | COVID-19         |                           |                   |
|    |                          |                  | 75%female                 |                   |
|    |                          |                  | –                         |                   |
|    |                          |                  | HIV                       |                   |
|    |                          |                  | WBC = 7.2                 |                   |
|    |                          |                  | Creatinine = 1.2          |                   |
|    |                          |                  | D-dimer = 1.98            |                   |
|    |                          |                  | Febrin = 69.2             |                   |
|    |                          |                  | IL6 = 64.1                |                   |
|    |                          |                  | Pro lactin = 0.21         |                   |
|    |                          |                  | LDH = 428                 |                   |
|    |                          |                  | Moderate/Severe            |                   |
|    |                          |                  | 17%                       |                   |
|    |                          |                  | 21%                       |                   |
| 18 | A. M. Shields [21]       | 100 patients     | 44%male                   |                   |
|    |                          | with PID and      |                           |                   |
|    |                          | symptomatic SID   |                           |                   |
|    |                          |                  | N = 60 (CVID               |                   |
|    |                          |                  | Undefined primary antibody |                   |
|    |                          |                  | deficiency XLA)           |                   |
|    |                          |                  | N = 40 (Chronic lung,     |                   |
|    |                          |                  | Cardiac-vascular,         |                   |
|    |                          |                  | Chronic liver disease,    |                   |
|    |                          |                  | Diabetes melitus)         |                   |
|    |                          |                  |                            |                   |
| 19 | N. Shalev [36]           | 31 PLWH          | Male 77%                  |                   |
|    |                          | Hospitalized for |                           |                   |
|    |                          | Coronavirus      |                           |                   |
|    |                          |                  |                            |                   |
| 20 | S. R. Nagarkanti [37]    | 23 HIV patients   | Male 51%                  |                   |
|    |                          | admitted for     |                           |                   |
|    |                          | COVID-19         |                           |                   |
|    |                          |                  |                            |                   |
| 21 | H. Miyashita [31]        | 161 HIV patients  | 60                         |                   |
|    |                          | with COVID-19     |                            |                   |
|    |                          |                  |                            |                   |

**Table 2 (continued)**

- **ID**: Identification number
- **First author (reference)**: Name of the first author and reference
- **Study population**: Description of the study population
- **COVID-19 mortality details**: Details about the mortality of COVID-19
- **Mortality Rate [%]**: Mortality rate in percentage

The table continues with similar entries for each study, including details about the study population, COVID-19 mortality details, and mortality rate.
| ID | First author (reference) | Study population | COVID-19 mortality details | Mortality Rate [N (%)] |
|----|--------------------------|------------------|-----------------------------|------------------------|
| 22 | I. Meyts [26]            | 94 patients with IEI with SARS-CoV-2 infection | 30 | 65% male | Primary antibody deficiency (56%) | ICU admission 20% | Asymptomatic 11% | Mild 25% | Hospitalization 63% | Other | 9.5% |

Data are represented as median (IQR), mean ±SD, or N (%)
frequently admitted to ICU compared with the general population. These findings warrant a recommendation for further stringent personal protective measures for patients affected by IEI [26]. However, this hypothesis might not seem that logical if we change our point of view. One of the main causes of the COVID-19 symptoms is the patient's immune system reaction leading to a cytokine storm in severe cases. From this point of view, a suppressed immune system might lower the chance of appearance of these symptoms. Referring to Fill et al. findings which state that the immunosuppression may be beneficial in preventing mortality, symptoms of hyperinflammation, and cytokine storm brought about by the SARS-CoV-2 virus interaction with the host immune responses, including interleukin (IL)-2, IL-6, IL-7, ferritin, and tumor necrosis factor-alpha among others[25]. In another study by van Oers et al. the lack of T cells, NK cells, and functional B cells in their patient did not lead to a fulminant or severe respiratory compromise, which is typical of COVID-19 disease [23].

Further analysis of our study results indicates that COVID-19 patients with primary immunodeficiencies (PIDs) have a markedly high mortality rate as well as a higher risk of infection with the SARS-CoV-2 virus. This may be highly attributed to the absence or poor function in one or more components of the immune system. It seems to be in line with a multi-center international analysis of 94 patients that were identified with an inborn error of immunity, of which 53 (56%) had primary antibody deficiency. They reported more than a third of all patients had CVID, but four of them died (45% of all deaths) [26]. Immunocompromised patients may be more susceptible to direct viral insult, which can cause organ damage and lead to morbidity and mortality, but those with combined immunodeficiency are at a larger risk [43]. In contrast to this, our study found that COVID-19 patients with CVID do not present additional mortality rates. Similarly, despite the presence of comorbidities, COVID-19 individuals with CVID had a minimal illness and did not require hospitalization. As a result, certain adaptive immune components do not appear to be required in management of SARS-CoV-2 infection. Rather, by lowering immunological-mediated consequences, these adaptive immune deficits may contribute to a milder course [26]. This, however, suggests that COVID-19 patients with CVID, compared with other forms of PIDs and the normal population, may be at a higher risk of infection but with a lower mortality

| Study                        | Selection (Out of 4) | Comparability (Out of 2) | Exposure/outcome (Out of 3) | Total score (Out of 9) |
|------------------------------|---------------------|--------------------------|-----------------------------|------------------------|
| Bhaskaran K [17]             | 4                   | 2                        | 3                           | 9                      |
| Cabello A [18]               | 4                   | 2                        | 3                           | 9                      |
| Childs K [28]                | 3                   | –                        | 3                           | 6                      |
| Cohen B [19]                 | 4                   | –                        | 3                           | 7                      |
| Del Amo J [32]               | 4                   | –                        | 3                           | 7                      |
| Delavari S [24]              | 4                   | –                        | 3                           | 7                      |
| Fill L [25]                  | 3                   | –                        | 3                           | 6                      |
| Gamboa E [38]                | 3                   | –                        | 3                           | 6                      |
| Geretti AM [39]              | 4                   | 2                        | 3                           | 9                      |
| Gervasoni C [33]             | 4                   | –                        | 3                           | 7                      |
| Hadi YB [29]                 | 4                   | 2                        | 3                           | 9                      |
| Härter G [34]                | 4                   | –                        | 3                           | 7                      |
| Ho H-e [30]                  | 4                   | 2                        | 3                           | 9                      |
| Karmen-Tuchy S [27]          | 4                   | 2                        | 3                           | 9                      |
| N.S.C. van Oers [23]         | 3                   | –                        | 3                           | 6                      |
| Douglas Tremblay [40]        | 4                   | –                        | 3                           | 7                      |
| K. Sigel [35]                | 4                   | 2                        | 3                           | 9                      |
| A. M. Shields [21]           | 4                   | 1                        | 3                           | 8                      |
| N. Shalev [36]               | 4                   | –                        | 3                           | 7                      |
| S. R. Nagarakanti [37]       | 4                   | 2                        | 3                           | 9                      |
| H. Miyashita [31]            | 4                   | –                        | 3                           | 7                      |
| I. Meyts [26]                | 3                   | –                        | 3                           | 6                      |
rate, indicating a good recovery rate for this category of patients [19]. However, PID patients under the category of SCID (Severe Combined Immunodeficiency) had a seemingly high risk of infection and death in our study. In concordance with our study, COVID-19 infection was found to be the deadliest among PID individuals in patients with SCID and familial hemophagocytic lymphohistiocytosis (FHL). This idea backs up the prior theory that SARS-CoV-2 is more deadly in patients with cellular immunodeficiency and immunological dysregulation, with a nearly 150-fold increased risk of death [24].

Another factor that appeared to influence the mortality and infection rate has been attributed to PID patients with underlying diseases before infection with COVID-19. Factors such as lymphoproliferation and history of lower respiratory infection in PID patients were observed in this group of people, recording high mortality rates.

SID is an acquired immunodeficiency due to a disease or environmental cause, such as malnutrition, human immunodeficiency virus (HIV), or medical treatment (e.g., radiotherapy, chemotherapy). Our analysis presented ten studies reporting a mortality rate >10% and seven studies presented a mortality rate of <10% in secondary immunodeficient subjects with COVID-19. We settled on case fatality >10% to be high. In all SID–COVID-19 cases, mortality ranged from 0% to as high as 41.7% [19, 44]. The most prominent SID among included studies was HIV and lesser cases involved cancer, hematologic malignancy, solid malignancy, etc. Some studies showed increased rates of mortality and morbidity and some showed the same or less rates than normal people. Bhaskaran K et al. discovered that individuals infected with HIV in England have an increased risk of COVID-19 death accounting for demographic and lifestyle-related factors, supporting the first point of view in the second type of immunodeficiency illnesses [17]. Comparable to them, Hadi YB et al. discovered that COVID-19 crude mortality is greater in HIV-positive individuals than in non-HIV patients; nonetheless, propensity-matched studies indicated no differences in outcomes, indicating that perhaps the higher mortality is attributable to the HIV patients’ higher load of underlying conditions and risk factors for severe COVID-19 [29].

The HIV attacks and impairs the body’s host defense system and causes immune deficiency. This immune deficiency lowers the severity of the immune system reactions against the SARS-CoV-2 virus, such as cytokine storms and the side effects that are caused by these reactions. It is important to note that if there are no comorbidities associated with HIV, the cytokine storm will be inhibited, and patients will have less serious symptoms and consequently low mortality rates [31]. However, according to our study, the case fatality rate is seemingly high in HIV patients with COVID-19, suggesting a higher death risk for this group of patients. Nevertheless, this high mortality rate in HIV–COVID-19 patients could be attributed to comorbid conditions and underlying diseases in this category of patients in our study. This strongly supports the hypothesis that HIV–COVID-19 patients have less serious symptoms and a low mortality rate due to the suppression of cytokine storm and its related effects provided that there are no comorbidities. The underlying diseases that could contribute to the high death rate include hypertension (HTN), diabetes mellitus (DM), end-stage renal disease (ESRD) or chronic kidney disease (CKD), cardiovascular disease (CD), hepatitis B and C, dyslipidemia, neurological disease (mainly dementia), rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), and coronary artery disease (CAD) [32]. Other demographic factors such as obesity and age >70 years play an important role in the death rate for this group of patients. Further analysis indicated that SID cases of cancer, hematologic malignancies, and solid malignancies presented the highest case mortality rate >40% in our study. This firmly suggests that COVID-19 patients in this category have an increased risk of infection and expiration. Interestingly, there was an intersection in underlying diseases that may have influenced the mortality rate in both PID–COVID-19 patients and SID–COVID-19 patients. Though HTN and DM intersected in both groups, no mortality was recorded in the PID cases, hence cannot be implicated in the death rate in this group. The reverse was observed in the SID cases [33, 45].

On the contrary, we have some studies in which the findings are controversial. These studies have the second point of view in the second type of immunodeficiency. Cabello A et al. findings show that neither the HIV severity nor the type of ARV treatment seems to influence the outcome of COVID-19 [18]. Similar to this point of view, Gervasoni C et al. found that patients infected with HIV and SARS-CoV-2 are not at a higher risk of developing severe disease or death than patients without HIV [33]. Similar to the previously mentioned studies, a study by Karmen-Tuohy S et al. shows that HIV coinfection did not affect the manifestation, hospital course, or prognosis of SARS-CoV-2 patients in comparison with matched non-HIV patients [27].

Limitations and recommendations
Clinical management and therapy of these two groups were not considered collectively, since the studies included had different clinical management of the disease and others did not include the type of therapy used. It is important to note that the therapy involved in each case could influence the clinical outcome (recovery or risk of
expiration), since most COVID-19 therapies are trials and patient management. Therefore, further studies are needed and highly recommended to focus on this aspect for patients suffering from both immunodeficiencies and COVID-19. This will enable clinicians to administer precise management and subsequently reducing COVID-19 mortality rates in immunodeficient patients.

Conclusions
The review of recent studies represents two points of view in both categories of immunodeficiency diseases. The classical viewpoint stipulates that all immunodeficient patients are at a higher risk of infection and consequently leading to a poor adverse outcome of COVID-19 serve as our first school of thought. However, our second perspective is in sharp contrast to this idea in which immunodeficiency may play a less important role in raising the rate of death by lowering the severity of the cytokine storm and its consequences. Both hypotheses have a noticeable number of supportive studies. Nonetheless, it is critical to recognize the role of comorbidities, such as COPD, DM, hypertension, CKD, history of lower respiratory infection, CAD, etc., and demographic factors, such as obesity and age > 70 years, in causing high COVID-19 mortality rates especially in SID individuals.

Acknowledgements
The present study was conducted in collaboration with Khalkhal University of Medical Sciences, Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, and University of Bergen.

Author contributions
The conception and design of the study: EM and SASA. Acquisition of data: AK, AB, and HM. Analysis and interpretation of data: PM, FV, and AB. Drafting the article: EM, SPM, PS, MR, and PYK. Revising it critically for important intellectual content: SASA and MMF. Final approval of the version to be submitted: EM, OD, and FV. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The authors stated that all information provided in this article could be shared.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent to publication
Not applicable.

Competing interests
The authors declare that there is no conflict of interest regarding the publication of this manuscript.

Author details
1Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. 2School of Medicine, Islamic Azad University, Tehran, Iran. 3Department of Pathology, Urmia University of Medical Sciences, Urmia, Iran. 4Department of Health Management, Policy & Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 5Department of Health Information Management, Faculty of Paramedical, Kashan University of Medical Sciences, Kashan, Iran. 6Biomedical Engineering Unit, University of Ghana Medical Center (UGMC), Accra, Ghana. 7Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran. 8Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. 9Graduation Program in Health Sciences, Faculty of Medicine, Federal University of Mato Grosso, Cuiabá, Mato Grosso, Brazil.

Received: 6 August 2021   Accepted: 24 September 2022
Published online: 08 October 2022

References
1. Organization WH. Coronavirus disease 2019 (COVID-19) situation report, 82. 2020.
2. Sheikhbahaei E, Mirghaderi SP, Moharrami A, Habibi D, Motitfard M, Mortazavi SMJ. Incidence of symptomatic COVID-19 in unvaccinated patients within 1 month after elective total joint arthroplasty: a multicenter study. Arthroplast Today. 2022;14:110–5.
3. Tantuoyir MA-O, Rezaei NA-O. Serological tests for COVID-19: potential opportunities. Cell Biol Int. 2021. https://doi.org/10.1002/cbi.11516.
4. Mirghaderi SP, Sheikhbahaei E, Salimi M, Mirghaderi SR, Ahmadi N, Moharrami A, et al. COVID-19 infection rate after urgent versus elective total hip replacement among unvaccinated individuals: a multicenter prospective cohort amid the COVID-19 pandemic. Ann Med Surg. 2022;80:104307.
5. Behnoush AH, Ahmadi N, Mozafar M, Mirghaderi SP, Azad AJ, Houaghan AK, et al. Anxiety, depression, and their contributing factors among nurses infected with COVID-19 in Iran: a cross-sectional study. Iranian Red Crescent Med J. 2022. https://doi.org/10.32592/ncmjr.2022.24.2.1519.
6. Momtazmanesh S, Shobeiri P, Hanaei S, Mahmoud-Elsayed H, Dalvi B, Rad EM. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. Egyptian Heart J. 2020;72(1):1–17.
7. Seyed ASA, Karimi A, Shobeiri P, Nowroozi A, Moeinaein E, Afshah AM, et al. Psychological symptoms of COVID-19 epidemic: a systematic review of current evidence. Psihologija. 2020. https://doi.org/10.2298/PSI2007030S35.
8. Thaweerat W. Current evidence on pancreatic involvement in SARS-CoV-2 infection. Pancreatology. 2020. https://doi.org/10.1016/j.pan.2020.05.015.
9. Xu Y, Liu P, Gu J. Gastrointestinal and liver involvement in patients with COVID-19. Lancet Gastroenterol Hepatol. 2020;5(9):798–9.
10. SeyedAlinaghi S, Karimi A, Mojdeganlou H, Allou S, Mirghaderi SP, Noori T, et al. Impact of COVID-19 pandemic on routine vaccination coverage of children and adolescents: a systematic review. Health Sci Rep. 2022;5(2):e00516.
11. Dadrass O, Afshah AM, Pashaei Z, Mojdeganlou H, Karimi A, Habibi P, et al. The relationship between COVID-19 viral load and disease severity: a systematic review. Immun Inflamm Dis. 2022;10(3):e580.
12. Meihraeen E, Olaei S, SeyedAllinaghi S, Karimi A, Mirzazapour P, Afshah AM, et al. COVID-19 in Pediatrics: a systematic review of current knowledge and practice. Infect Disord Drug Targets. 2022;22(2):47–57.
13. Nasab MG, Saghzadeh A, Rezaei N. SARS-CoV-2-A tough opponent for the immune system. Archives Med Res. 2020. https://doi.org/10.1016/j.arcmed.2020.05.020.
14. Yazdanparah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci. 2020. https://doi.org/10.1016/j.lfs.2020.11.7900.
15. Gernez Y, Baker MG, Maglione PJ. Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy. Transfusion. 2018;58(Suppl 3):3056–64.
16. Chamberland ME, Ciesielski CA, Howard RJ, Fry DE, Bell DM. Occupational risk of infection with human immunodeficiency virus. Surg Clin North Am. 1995;75(6):1057–70.
17. Bhaskaran K, Rentsch CT, MacKenna B, Schulz A, Mehrkar A, Bates CJ, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet. HIV. 2021;8(1):e24–32.

18. Cabelló A, Zamarro B, Nistal S, Víctor V, Hernández J, Prieto-Pérez L, et al. COVID-19 in people living with HIV: a multicenter case-series study. Int J Infect Dis. 2021;102:310–5.

19. Cohen B, Rubinstein R, Gans MD, Deng L, Rubinstein A, Eisenberg R. COVID-19 infection in 10 common variable immunodeficiency patients in New York City. J Allergy Clin Immunol Pract. 2021;9(1):504–7.e1.

20. Mehraeen E, Karimi A, Barzegary A, Vahedi F, Afshahi AM, Dadras O, et al. Predictors of mortality in patients with COVID-19: a systematic review. Eur J Integr Med. 2020;40:101226.

21. Shields AM, Burns SO, Savic S, Richter AG. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. J Allergy Clin Immunol. 2021;147(3):380-5.e1.

22. Meira CM Jr, Menegueli KS, Leopoldo MPG, Florindo AA. Anxiety and Leisure-domain physical activity frequency, duration, and intensity during Covid-19 Pandemic. Front Psychol. 2020;11: 603770.

23. van Oers NSC, Hanners NW, Sue PK, Aquino V, Li Q-Z, Schoggins JW, et al. SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency. Clin Immunol. 2021;224: 108662.

24. Childs K, Post FA, Norcross C, Ottaway Z, Hamlyn E, Quinn K, et al. Hospitalized patients with COVID-19 and human immunodeficiency virus: a case series. J Clin Immunol. 2021;41(2):345–55.

25. Fill I, Hadney L, Graven K, Persaud R, Hostoffer R. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125(1):112–4.

26. Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoeane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147(2):520–31.

27. Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr. 2020;95(10):1054.

28. Childs K, Post FA, Norcross C, Ottaway Z, Hamlyn E, Quinn K, et al. Hospitalized patients with COVID-19 and human immunodeficiency virus: a case series. Clin Infect Dis. 2020;71(8):2021–2.

29. Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study. AIDS. 2020;34(13):F3–8.

30. Ho H-e, Peluso MJ, Margus C, Matias Lopes JP, He C, Gasa MM, et al. Clinical outcomes and immunologic characteristics of coronavirus disease 2019 in people with human immunodeficiency virus. J Infect Dis. 2021;223(3):403–8.

31. Miyashita H, Kuno T. Prognosis of coronavirus disease 2019 (COVID-19) in patients with HIV infection in New York City. HIV Med. 2021;223(3):403–8.

32. Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2020;173(7):536–41.

33. Gervasoni C, Mervaglia P, Riva A, Giacomelli A, Oreni L, Minisci D, et al. Clinical features and outcomes of patients with human immunodeficiency virus with COVID-19. Clin Infect Dis. 2020;71(6):2276–8.

34. Härter G, Spinner CD, Roijer J, Bickel M, Krznaric I, Grunwald S, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection. 2020;48(5):681–6.

35. Sigel K, Swartz T, Golden E, Paranjpe I, Somani S, Richter F, et al. Coronavirus 2019 and people living with human immunodeficiency virus: outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020;71(11):2933–8.

36. Stahler N, Scherer M, LaSota ED, Antoniou P, Yin MT, Zucker J, et al. Clinical characteristics and outcomes in people living with human immunodeficiency virus hospitalized for coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2294–7.

37. Nagarakanti SR, Okoh AK, Grinberg S, Bishburg E. Clinical outcomes of patients with COVID-19 and HIV coinfection. J Med Virol. 2021;93(3):1687–93.

38. Gernsbach E, Duran M, Gathe JC Jr, Surani S, Varon J. COVID-19 coexisting with the human immunodeficiency virus: a case report. Cureus. 2020. https://doi.org/10.7759/cureus.11007.

39. Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARC world health organization (WHO) clinical characterization protocol (UK): a prospective observational study. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1605.

40. Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, et al. Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients. Cancer. Med. 2020;9(22):8571–8.

41. SeyedAli Naghsh SAS, Mehrtabi M, MohseniPour M, Mirzapour P, Barzegary A, Habibi P, et al. Genetic susceptibility of COVID-19: a systematic review of current evidence. Eur J Med Res. 2021;26(1):46.

42. Dadras O, Ali Naghsh SAS, Karimi A, MohseniPour M, Barzegary A, Vahedi F, et al. Effects of COVID-19 prevention procedures on other common infections: a systematic review. Eur J Med Res. 2021;26(1):67.

43. Ahanchian H, Moazzen N, Joghatahi SH, Saeidinia A, Khoshkhi M, Aelami MH, et al. Death due to COVID-19 in an infant with combined immunodeficiencies. JID. 2020. https://doi.org/10.1174/1871393326666201021142313.

44. Tremblay DA-O, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, et al. Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients. Cancer Med. 2020. https://doi.org/10.1002/cam4.3457.

45. Härter G, Spinner CD, Roijer J, Bickel M, Krznaric I, Grunwald S, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection. 2020;48:681–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.